Journal Article

Prediction of Benefit From Adjuvant Pertuzumab by 80-Gene Signature in the APHINITY (BIG 4-11) Trial

  • Krop I
  • Mittempergher L
  • Paulson J
  • et al.
JCO Precision Oncology (2024) (8)
DOI: 10.1200/po.22.00667
1Citations
Citations of this article
4Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Adjuvant pertuzumab benefit prediction by the 80-gene BluePrint signature in the APHINITY (BIG 4-11) trial #BIGNetwork #APHINITYtrial

Cite

CITATION STYLE

APA

Krop, I. E., Mittempergher, L., Paulson, J. N., Andre, F., Bonnefoi, H., Loi, S., … Piccart, M. J. (2024). Prediction of Benefit From Adjuvant Pertuzumab by 80-Gene Signature in the APHINITY (BIG 4-11) Trial. JCO Precision Oncology, (8). https://doi.org/10.1200/po.22.00667

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free